Track topics on Twitter Track topics that are important to you
MabPlex, a biologics CDMO located in Yantai, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital, two state-owned investors. Founded in 2013, MabPlex offers biologics development and manufacturing services, including mAbs, recombinant proteins, ADCs and bispecifics. Its offerings range from gene sequencing to cell line development and commercial production. MabPlex’s CHO cell line platform is designed to move candidates in the shortest possible time from DNA to finished product. In 2018, MabPlex opened a
Share this with colleagues:
Original Article: MabPlex, a China Biologic CDMO, Closes $59 million Series ANEXT ARTICLE
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...